These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2031 related articles for article (PubMed ID: 25673644)
1. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
3. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322 [TBL] [Abstract][Full Text] [Related]
4. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202 [TBL] [Abstract][Full Text] [Related]
5. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798 [TBL] [Abstract][Full Text] [Related]
6. Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. Meador CB; Pao W Cancer Discov; 2015 Apr; 5(4):348-50. PubMed ID: 25847954 [TBL] [Abstract][Full Text] [Related]
7. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991 [TBL] [Abstract][Full Text] [Related]
8. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154 [TBL] [Abstract][Full Text] [Related]
9. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282 [TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Temraz S; Mukherji D; Shamseddine A Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261 [TBL] [Abstract][Full Text] [Related]
11. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in Hazar-Rethinam M; Kleyman M; Han GC; Liu D; Ahronian LG; Shahzade HA; Chen L; Parikh AR; Allen JN; Clark JW; Kwak EL; Faris JE; Murphy JE; Hong TS; Van Seventer EE; Nadres B; Hong CB; Gurski JM; Jessop NA; Dias-Santagata D; Iafrate AJ; Van Allen EM; Corcoran RB Cancer Discov; 2018 Apr; 8(4):417-427. PubMed ID: 29431697 [TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
13. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Oddo D; Sennott EM; Barault L; Valtorta E; Arena S; Cassingena A; Filiciotto G; Marzolla G; Elez E; van Geel RM; Bartolini A; Crisafulli G; Boscaro V; Godfrey JT; Buscarino M; Cancelliere C; Linnebacher M; Corti G; Truini M; Siravegna G; Grasselli J; Gallicchio M; Bernards R; Schellens JH; Tabernero J; Engelman JA; Sartore-Bianchi A; Bardelli A; Siena S; Corcoran RB; Di Nicolantonio F Cancer Res; 2016 Aug; 76(15):4504-15. PubMed ID: 27312529 [TBL] [Abstract][Full Text] [Related]
14. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]